Clinical trial readout dates for Praxis Precision Medicines Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 3 1mg elsunersen Epileptic Encephalopathy; SCN2A Encephalopathy · NCT07019922 | December 2026 Recruiting |
| Phase 3 1.0mg/kg/day PRAX-562 Developmental and Epileptic Encephalopathy 1 · NCT07010471 | December 2026 Ongoing |
| Phase 3 40 mg/day vormatrogine for 12 weeks Focal Epilepsy · NCT07505004 | January 2027 Ongoing |
| Phase 3 vormatrogine Epilepsy, Tonic-Clonic; Focal Seizure · NCT07287163 | May 2028 Enrolling |
Praxis Precision Medicines Inc. reported $1.84B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $94M; at that rate the cash would last about 20 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-11-12 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |